

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Lee's Pharmaceutical Holdings Limited**

**李氏大藥廠控股有限公司\***

*(incorporated in the Cayman Islands with limited liability)*

(Stock Code: 8221)

### **PROPOSED TRANSFER OF LISTING OF THE SHARES FROM THE GROWTH ENTERPRISE MARKET TO THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED**

The Directors are pleased to announce that on 10 March 2010 the Company made an application to the Stock Exchange for the transfer of listing of the Shares from GEM to the Main Board of the Stock Exchange pursuant to the streamlined transfer of listing procedures under Chapter 9A of the Main Board Listing Rules.

The directors (the “**Directors**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”) are pleased to announce that on 10 March 2010, the Company made an application to The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) for the transfer of listing of all its issued ordinary shares of par value of HK\$0.05 each (the “**Shares**”) from the Growth Enterprise Market of the Stock Exchange (“**GEM**”) to the Main Board of the Stock Exchange (the “**Transfer of Listing**”) pursuant to the streamlined transfer of listing procedures under Chapter 9A of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Main Board Listing Rules**”).

The Directors believe that the Transfer of Listing will enhance the profile and corporate image of the Company and its subsidiaries (the “**Group**”) and can improve the trading liquidity of the Shares. The Directors consider that the Transfer of Listing will also be beneficial to the future growth, financing flexibility and business development of the Group. As at the date of this announcement, no plan of change in nature of business of the Group following the Transfer of Listing is contemplated by the Directors. The Transfer of Listing will not involve issue of any new Shares by the Company.

The Company will make further announcement(s) in relation to the progress of the Transfer of Listing.

\* For identification purpose only

**Shareholders and potential investors should be aware that the implementation of the Transfer of Listing is subject to, among others, the granting of relevant approval by the Stock Exchange and thus the Transfer of Listing may or may not proceed. Shareholders and potential investors should exercise caution when dealing in the Shares.**

By order of the Board  
**Lee's Pharmaceutical Holdings Limited**  
*Lee Siu Fong*  
**Chairman**

Hong Kong, 10 March 2010

*As at the date of this announcement, Ms. Lee Siu Fong, Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive Directors; Mr. Mauro Bove is non-executive Director; Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this announcement is accurate and complete in all material respects and not misleading; (ii) there are no other matters the omission of which would make any statement in this announcement misleading; and (iii) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*

*This announcement will remain on the GEM website at [www.hkgem.com](http://www.hkgem.com) on the "Latest Company Announcements" page for at least 7 days from the date of its posting and on the website of the Company at [www.leespharm.com](http://www.leespharm.com).*